Articles On Medadvisor (ASX:MDR)
Title | Source | Codes | Date |
---|---|---|---|
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | MDR | 5 days ago |
Buy Coles and these ASX dividend stocks
If you're on the look at for some ASX dividend stocks to buy for your income portfolio, then you may want to check out the three listed below. Here's what you need to know about these income options: Coles Group Ltd (ASX: COL) Analysts at... |
Motley Fool | MDR | 1 week ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | MDR | 1 week ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) enjoyed another positive session today, as the recovery from last week's slump continues. A confident session saw the ASX 200 add a decent 0.4... |
Motley Fool | MDR | 1 week ago |
Market Close: ASX drives uphill on continued recovery
The ASX200 closed .4 of a per cent up with IT and Health Care the locomotives of a sluggish steam energy labouring under the weight of Energy and Industrials. IT and Health Care were up 1.73 and 1.22 per cent respectively whilst Energy a... |
themarketonline.com.au | MDR | 1 week ago |
Will the Reserve Bank wait for the US Fed to cut interest rates first?
While the US economy is seen as a leading indicator for the world, the US Fed is unlikely to be the first major central bank to start cutting interest rates, says AMP deputy chief economist Diana Mousina. Mousina points out that the US... |
Motley Fool | MDR | 1 week ago |
Healthco Healthcare, Medadvisor, Ramsay Health Care, and Tamboran shares are rising
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is pushing higher again. At the time of writing, the benchmark index is up 0.4% to 7,681.2 points. Four ASX shares that are rising more than most today are listed below. Here's why... |
Motley Fool | MDR | 1 week ago |
Wesfarmers shares baulk on fresh acquisition gossip
The Wesfarmers Ltd (ASX: WES) share price is treading water today on fresh acquisition rumours. Shares in the diverse retailing conglomerate are down 0.4% to $65.33. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is up 0.4%. After a... |
Motley Fool | MDR | 1 week ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | MDR | 2 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | MDR | 2 months ago |
MedAdvisor invests $1.9m in UK pharmacy app for 7.4pc share
MedAdvisor will pay £1 million (A$1.9 million) to UK pharmacy market app provider Charac Charac will see MedAdvisor pick up a 7.4 per cent shareholding MedAdvisor’s Rick Ratliff will become an NED on Charac’s board MedAdvisor wi... |
themarketherald.com.au | MDR | 5 months ago |
TMH Market Close: ASX200 slumps 0.76pc as real estate drags, IT edges higher
So much for a small rise on the market today. Instead, the ASX200 closed down about three quarters (.76) per cent. Real estate stocks proved the biggest drag, down just over one and a quarter of a per cent, while IT was the only sector t... |
themarketherald.com.au | MDR | 5 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | MDR | 5 months ago |
ASX Health Stocks: Amplia’s pancreatic cancer trial gets boost; Emyria’s MDMA therapy is one step closer
Amplia reports positive data from pancreatic cancer trial Emyria was given endorsement by ethical committee for its TGA application MedAdvisor’s Q1 sales were up 27pc Amplia reports promising data from pancreatic cancer trial Amplia The... |
Stockhead | MDR | 6 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | MDR | 6 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | MDR | 7 months ago |
Closing Bell: Local markets shed 0.6pc as we brace for tonight’s US Fed call
The ASX 200 benchmark falls 0.6% as we brace for news from The Fed Sector losses led by Resources, while Consumers make gains Small caps led by Alderan, and BNPL Sezzle returns Local markets made it a hat trick of losses, with the re... |
Stockhead | MDR | 7 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | MDR | 7 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | MDR | 8 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | MDR | 8 months ago |
Market Highlights: US tech stocks rally, dividends at all-time high, and 5 ASX small caps to watch today
ASX is set to rise for a third consecutive day Tech stocks in the US rallied overnight after a soft jobs market report Dividends rose in Q2 in Australia and around the world The ASX is set to open higher for a third consecutive day afte... |
Stockhead | MDR | 8 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | MDR | 8 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | MDR | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | MDR | 10 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | MDR | 10 months ago |
MoneyTalks: Why Salter Brothers is eyeing ASX small cap medtechs
MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Salter Broth... |
Stockhead | MDR | 11 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | MDR | 11 months ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | MDR | 1 year ago |
Dr Boreham’s Crucible: Are MedAdvisor’s US plans about to go to script?
Despite the billions of dollars spent on developing new drugs, many of them are ineffective for a large number of patients. Is that a Big Pharma conspiracy to be revealed on the ABC’s Four Corners next Monday night? Er – no, actually. The... |
Stockhead | MDR | 1 year ago |
Medadvisor [ASX:MDR] Transitions Back into Profit for Half-Year 2023
Medadvisor [ASX:MDR], Australian developer of healthcare software for patients, announced its return back into profit in its half-year 2023 results announcement — declaring profits had surged 161%. Investors were tipping the MDR share price... |
Daily Reckoning | MDR | 1 year ago |
Top 10 at 10: Which ASX stocks are flying and floundering on Friday?
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | MDR | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | MDR | 1 year ago |
Top 10 at 10: Which ASX exploration stocks are hitting paydirt today?
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | MDR | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | MDR | 1 year ago |
ASX December Winners: Who’s led the way for small caps in tough month for global markets?
Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p... |
Stockhead | MDR | 1 year ago |
ASX Director Trades: Which Meteoric Resources director buys up big in the December winner?
December winner Meteoric Resources sees a non-executive director buy 6 million shares Northern Star Resources and Chalice Mining directors sell in December for tax obligations Johns Lyng Group COO Lindsay Barber sells 4 million shares, ~3... |
Stockhead | MDR | 1 year ago |
5 things to watch on the ASX 200 on Thursday
On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was back on form and charged notably higher. The benchmark index rose 1.3 % to 7,115.1 points. Will the market be able to build on this on Thursday? Here are five things to watch: ASX 20... |
Motley Fool | MDR | 1 year ago |
Could ASX 200 gold shares be ‘at another pivot point’?
ASX 200 gold shares soared on Wednesday, but could a ‘pivot point’ for the gold price be on the way? Gold producers on the ASX 200 include Evolution Mining Ltd (ASX: EVN), Newcrest Mining Ltd (ASX: NCM), and Northern Star Resources Lt... |
Motley Fool | MDR | 1 year ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) bounced back from yesterdayâs chaos today. The index closed 1.3% higher at 7,115.1 points. Leading todayâs gains on the Aussie bourse was the S&P/ASX 200 Utilities Index (ASX: XUJ). It rose 3.8%... |
Motley Fool | MDR | 1 year ago |
Here are the 3 most heavily traded ASX 200 shares on Wednesday
The S&P/ASX 200 Index (ASX: XJO) has shaken off the malaise that has been gripping it this week and posted a strong gain at this point of Wednesday’s trading session. At the time of writing, the ASX 200 has gained a very healthy 1.35%,... |
Motley Fool | MDR | 1 year ago |
Why are ASX 200 gold shares having such a stellar run today?
ASX 200 gold shares are having a top run on the market today amid higher gold prices. Gold explorers in the green include Evolution Mining Ltd (ASX: EVN), Newcrest Mining Ltd (ASX: NCM) and Northern Star Resources Ltd (ASX: NST) Let’s tak... |
Motley Fool | MDR | 1 year ago |
Why you should pay attention to the Bank of Japan
Investors were caught off guard yesterday after the Bank of Japan (BoJ) broke decades of monetary tradition. The central bank’s decision to widen the acceptable band on the country’s risk-free rate was met with blood in equity markets. In... |
Motley Fool | MDR | 1 year ago |
Why European Lithium, Evolution, Medadvisor, and REA shares are charging higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has bounced back from yesterdayâs selloff. At the time of writing, the benchmark index is up 1.3% to 7,117.2 points. Four ASX shares that are climbing more than most today are lis... |
Motley Fool | MDR | 1 year ago |
Stocks of the Hour: Matrix Composites & Engineering, DroneShield, MedAdvisor
21 Dec 2022 - A snapshot of the stocks on the move featuring Matrix Composites & Engineering (ASX:MCE), DroneShield (ASX:DRO) and MedAdvisor (ASX:MDR). |
FNN | MDR | 1 year ago |
MedAdvisor expects 50-60% revenue growth as US expansion accelerates
This content is created by Smallcaps Authors. [Author : Lorna Nicholas] MedAdvisor (ASX: MDR) has revealed it expects revenue for the six months ending December 2022 (H1 FY2023) to be up 50-60% on H1 FY2022 levels due to the company’s US... |
SmallCaps | MDR | 1 year ago |
MedAdvisor’s US digital strategy set to boost first-half revenue by up to 60pc
An acquisitive couple of years is starting to pay off for pharmacy tech company MedAdvisor (ASX: MDR) which has forecast a spike of between 50 and 60 per cent in first-half revenue for FY23. MedAdvisor is expecting revenue to land between... |
businessnewsaustralia.com | MDR | 1 year ago |
Market Highlights: Oh, BoJ, what have you done… and 5 ASX small caps to watch today
Markets overnight were scrambling to adjust to a shock move by the Bank of Japan to allow the yield on 10-year Japanese government bonds to shift up to 0.50 per cent instead of its long-preferred 0.25 per cent cap. In a nutshell, Japan’s be... |
Stockhead | MDR | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | MDR | 1 year ago |
3 ASX healthcare shares punished following full-year results
ASX healthcare shares have been a mixed bag this earnings season, with some names completely blowing it out of the park, whereas others have left more to be desired. The S&P/ASX 200 Health Care index (ASX: XHJ) finished up 122 basis p... |
Motley Fool | MDR | 1 year ago |
MoneyTalks: 3 ‘below-the-radar’ ASX stocks to watch in the second half of 2022
MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Equitable In... |
Stockhead | MDR | 1 year ago |